ERBB2 and breast carcinoma: Trastuzumab (TZ)-grafted dendrimers loaded with docetaxel (DTX) were tested against HER2-positive breast cancer cells and the data showed that dendrimers were more selective with the enhanced site-specific delivery of DTX, had less systemic toxicity, increased the anti-proliferation potential, increased cellular internalization, enhanced apoptosis inMDA-MB-231 and MDA-MB-453 human breast cancer cells, and could efficiently be used in breast cancer patients [46].